Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America

John L. Goudreau, Adriana Pérez, Michael J. Aminoff, James T. Boyd, Keith D. Burau, Chadwick W. Christine, Maureen Leehey, John C. Morgan

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180 days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.

Original languageEnglish (US)
Pages (from-to)74-81
Number of pages8
JournalJournal of the Neurological Sciences
StatePublished - Jul 15 2016


  • Clinical trial
  • Dopamine agonists
  • Levodopa

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America'. Together they form a unique fingerprint.

Cite this